Capital World Investors Revance Therapeutics, Inc. Transaction History

Capital World Investors

$586 Billion
Q1 2024

A detailed history of Capital World Investors transactions in Revance Therapeutics, Inc. stock. As of the latest transaction made, Capital World Investors holds 13,945,535 shares of RVNC stock, worth $35.8 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

13,945,535

Previous 11,939,076 16.81%

Holding current value

$35.8 Million

Previous $105 Million 34.62%

% of portfolio

0.01%

Previous 0.02%

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$4.65 - $9.31 $9.33 Million - $18.7 Million	2,006,459 Added 16.81%	13,945,535 $68.6 Million
Q4 2023 Feb 13, 2024	SELL	$5.81 - $11.2 $126,332 - $243,532	-21,744 Reduced 0.18%	11,939,076 $105 Million
Q3 2023 Nov 13, 2023	BUY	$11.47 - $25.07 $27.4 Million - $59.8 Million	2,385,946 Added 24.92%	11,960,820 $137 Million
Q2 2023 Aug 11, 2023	SELL	$24.7 - $37.61 $12.4 Million - $18.9 Million	-501,227 Reduced 4.97%	9,574,874 $242 Million
Q1 2023 May 15, 2023	BUY	$18.36 - $35.27 $10.9 Million - $21 Million	595,945 Added 6.29%	10,076,101 $325 Million

Q4 2022 Feb 14, 2023	BUY	$18.32 - $30.66 $26.2 Million - $43.9 Million	1,431,318 Added 17.78%	9,480,156 $175 Million
Q3 2022 Nov 14, 2022	BUY	$14.33 - $28.47 $49.6 Million - $98.5 Million	3,458,838 Added 75.36%	8,048,838 $217 Million
Q2 2022 Aug 15, 2022	BUY	$11.52 - $20.4 $14.3 Million - $25.3 Million	1,240,000 Added 37.01%	4,590,000 $63.4 Million
Q1 2022 May 16, 2022	SELL	$12.36 - $20.31 $4.47 Million - $7.35 Million	-362,000 Reduced 9.75%	3,350,000 $65.3 Million
Q4 2021 Feb 14, 2022	BUY	$12.46 - $27.87 $9.28 Million - $20.8 Million	745,000 Added 25.11%	3,712,000 $60.6 Million
Q2 2021 Aug 16, 2021	BUY	$26.8 - $31.84 $10.6 Million - $12.6 Million	395,898 Added 15.4%	2,967,000 $87.9 Million
Q1 2021 May 14, 2021	BUY	$24.03 - $29.97 $10.6 Million - $13.2 Million	441,102 Added 20.71%	2,571,102 $71.9 Million
Q4 2019 Feb 18, 2020	BUY	$11.66 - $20.15 $5.19 Million - $8.97 Million	445,000 Added 26.41%	2,130,000 $34.6 Million
Q1 2019 May 15, 2019	BUY	$15.4 - $20.39 $7.08 Million - $9.38 Million	460,000 Added 37.55%	1,685,000 $26.6 Million
Q3 2018 Nov 14, 2018	SELL	$23.55 - $30.1 $4.95 Million - $6.32 Million	-210,000 Reduced 14.63%	1,225,000 $30.4 Million
Q2 2018 Aug 14, 2018	BUY	$27.45 - $33.35 $39.4 Million - $47.9 Million	1,435,000 New	1,435,000 $39.4 Million

Others Institutions Holding RVNC

# of Institutions

215

Shares Held

83.4M

Call Options Held

656K

Put Options Held

424K

View Full List

About Revance Therapeutics, Inc.

Ticker RVNC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,305,696
Market Cap $212M
Description
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...

More about RVNC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital World Investors, based on Form 13F filings with the SEC.

News

Stay updated on Capital World Investors with notifications on news.

Account

Capital World Investors Revance Therapeutics, Inc. Transaction History